Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the completion of the sale, the director now directly owns 2,071,931 shares in the company, valued at $221,945,248.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Noubar Afeyan also recently made the following trade(s):
- On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total transaction of $1,525,200.00.
- On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00.
- On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $102.39, for a total transaction of $1,535,850.00.
- On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.
Moderna Trading Down 1.7 %
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Shares of Moderna stock opened at $105.14 on Friday. The stock has a market cap of $40.26 billion, a price-to-earnings ratio of -8.47 and a beta of 1.62. The company has a fifty day simple moving average of $99.71 and a 200-day simple moving average of $93.52. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $163.24.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna's quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.61 EPS. On average, equities analysts forecast that Moderna, Inc. will post -7.48 EPS for the current fiscal year.
Hedge Funds Weigh In On Moderna
A number of large investors have recently bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new position in shares of Moderna in the 4th quarter valued at about $27,000. First Pacific Financial acquired a new stake in shares of Moderna during the 3rd quarter worth about $27,000. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna during the 4th quarter worth about $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock worth $29,000 after purchasing an additional 290 shares during the last quarter. Finally, Rise Advisors LLC boosted its stake in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company's stock worth $34,000 after purchasing an additional 286 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a "hold" rating in a research note on Friday, February 23rd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research note on Thursday. Jefferies Financial Group reaffirmed a "buy" rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday. Finally, Oppenheimer raised shares of Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 target price on the stock in a research note on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Moderna has a consensus rating of "Hold" and a consensus price target of $126.49.
Get Our Latest Analysis on MRNA
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
